EGFR-activating mutations are known to be associated with response to EGFR-TKI therapy, and we thus set out to evaluate the correlation between HX103 labeling and EGFR-activating mutations in surgical specimens from NSCLC patients. This evidence concerns the gene EGFR and non-small cell lung carcinoma.